Loading...
•
Jun 30, 2024
AN2 Therapeutics Q2 2024 Earnings Report
AN2 Therapeutics reported financial results for the second quarter of 2024.
Key Takeaways
AN2 Therapeutics reported a net loss of $14.4 million for Q2 2024, compared to a net loss of $15.8 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $104.5 million as of June 30, 2024, expected to fund operations through 2027. The company is shifting its focus to its internal boron chemistry platform and ongoing pipeline programs.
Reported topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole in treatment-refractory MAC lung disease, which met its primary objective but had similar sputum culture conversion rates between treatment arms.
Terminated the Phase 2 and Phase 3 parts of the EBO-301 trial based on topline data.
Published new epetraborole data in Antimicrobial Agents in Chemotherapy, highlighting its efficacy against M. abscessus in a mouse lung infection model.
Cash, cash equivalents, and investments of $104.5 million at June 30, 2024, are anticipated to fund operations through 2027.
AN2 Therapeutics
AN2 Therapeutics
Forward Guidance
AN2 Therapeutics plans to advance two development programs into clinical trials in 2025, focusing on AN2-502998 for Chagas disease and epetraborole for melioidosis. The company also has a pipeline of internally developed boron-based compounds targeting unmet needs in infectious disease and oncology.
Positive Outlook
- AN2-502998 is expected to enter Phase 1 with an aim to cure chronic Chagas disease.
- Plans to initiate a Phase 2 trial with epetraborole for the treatment of melioidosis.
- Pipeline of internally developed boron-based compounds in research targeting high unmet needs in infectious disease and oncology.
- Financial runway to allow achievement of multiple inflection points over the next three years.
- Epetraborole shows efficacy against M. abscessus in a mouse lung infection model.
Challenges Ahead
- Termination of Epetraborole Pivotal Phase 2/3 Clinical Study in TR-MAC Lung Disease.
- Sputum culture conversion at Month 6 was similar between treatment arms in the EBO-301 trial.
- Uncertainty associated with product candidates ever receiving any regulatory approvals.
- Potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results.
- Risks related to timely enrollment of patients in clinical trials.